Why Madrigal Pharmaceuticals Is On Investors’ Radar

Madrigal Pharmaceuticals (MDGL) has drawn attention after a recent move in its share price, with the stock up 3.1% over the past day but showing weaker returns over the past month.

The 3.1% one-day share price gain comes after weaker recent momentum, with a 30-day share price return of a 14.9% decline and a year-to-date share price return of a 19.6% decline. However, the 1-year total shareholder return of 43.5% and 5-year total shareholder return approaching 3x highlight that longer-term holders have still seen strong gains.

If this MASH-focused story has caught your attention, it could be a good moment to broaden your research with our screener of 26 healthcare AI stocks that the market is watching closely.

With Madrigal sharing a strong 1 year and 5 year total return, yet trading at what some see as a discount to analyst targets and intrinsic value, is this a genuine opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 20.9% Undervalued

At a last close of $477.60 versus a narrative fair value of $603.47, Madrigal Pharmaceuticals is framed as undervalued, with that gap heavily tied to expectations around Rezdiffra’s long runway.

The rapid uptake and long-term patent protection of Rezdiffra, supported by a new U.S. patent that extends exclusivity to 2045, provides decades of protected revenue opportunity; this increases the likelihood of sustained top-line growth and supports margin expansion due to extended pricing power.

Curious what kind of revenue ramp and margin profile could support that valuation gap? The narrative leans on compound growth, richer profitability and a future earnings multiple usually reserved for sector standouts. Want to see the exact assumptions that back into that fair value and how they stack up against current losses and share count expectations?

Result: Fair Value of $603.47 (UNDERVALUED)

However, you also have to weigh real risks here, including Madrigal’s reliance on Rezdiffra and the potential impact of GLP 1 competition on pricing and future uptake.

Another Angle On Value

Our DCF model presents a different perspective. On this view, Madrigal at $477.60 is trading well below an estimated future cash flow value of $1,890.54 per share. This frames the stock as heavily undervalued and raises the question of whether this represents a margin of safety or a sign that expectations are running too far ahead.

Build Your Own Madrigal Pharmaceuticals Narrative

If you look at this and think the assumptions feel off, or you would rather test your own inputs against the data, you can build a custom Madrigal view in just a few minutes and see how your story compares, starting with Do it your way.

A great starting point for your Madrigal Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If Madrigal has sparked your interest, do not stop here; use the Simply Wall St screener to line up other opportunities that actually fit your style and goals.

• Target potential value opportunities by scanning companies trading on compelling fundamentals using our 53 high quality undervalued stocks that many investors are watching closely.
• Prioritise resilience by reviewing companies flagged in the 86 resilient stocks with low risk scores so you can focus on businesses with lower overall risk scores.
• Hunt for lesser known opportunities by working through our screener containing 24 high quality undiscovered gems that highlight strong fundamentals away from the usual headlines.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.